DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Find active GLP‑1 trials in your area — retatrutide (triple agonist), CagriSema, CT-388, orforglipron, survodutide. Generates ClinicalTrials.gov + SubjectWell search URLs by indication + ZIP.
Next-gen GLP-1 compounds in active Phase 3 trials
Retatrutide (Eli Lilly triple agonist) showing 24%+ weight loss. CagriSema (Novo) combining semaglutide + cagrilintide. CT-388 (Roche) dual GLP-1/GIP. Survodutide (Boehringer) GLP-1/glucagon. Most expect FDA approval 2027-2028. Trials = early access.
Trial search criteria
Access to next-gen compounds before FDA approval: retatrutide (triple agonist showing 24%+ weight loss), CagriSema (semaglutide + cagrilintide), CT-388 (Roche dual GLP-1/GIP). Free medication + monitoring. Trials may require placebo group — disclosed upfront.
Some trials pay stipends ($200-2000 typical) for time + transportation. Phase 1 (healthy volunteers) pays more. Phase 2-3 (efficacy in disease populations) often pays less but provides free medication. Always read informed consent.
Midi Health and similar route patients into retatrutide and other Phase 3 trials. Real — but with caveats: placebo possibility, frequent visits, lab monitoring, stricter eligibility. Treat as research participation, not a free-medication shortcut.
Most trials require washout period (8-12 weeks off current GLP-1) before enrollment. Some next-gen trials specifically enroll GLP-1 non-responders or those wanting to switch — check eligibility carefully.
Phase 3 trials enroll thousands of patients with established safety from Phase 1-2. FDA approval pending means efficacy is being confirmed, not safety. Trial drugs that reach Phase 3 have already passed strict safety thresholds.
Yes — many obesity medicine + endocrinology specialists know about local trials. Ask explicitly. Also: SubjectWell + ResearchMatch (NIH) + Antidote's trial search can match you based on your profile.
Research participation ≠ guaranteed treatment. Trials may include placebo arm. Read informed consent thoroughly. Discuss with prescriber before enrollment. Don\'t stop existing GLP-1 to qualify for trial without medical guidance.